Prostate Cancer: How Long Can You Expect to Survive? (2026 Update)

Prostate cancer is a cancer with a very high 5-year relative survival rate of 96.9%, according to National Cancer Registry Statistics for 2019–2023. However, this figure is a nationwide average, and actual prognosis varies significantly depending on risk group, stage, and age.

Key summary

• The 5-year relative survival rate for prostate cancer in Korea is 96.9% (National Cancer Registry Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry). This is up 37.7 percentage points from patients diagnosed in 1993–1995.
• In the United States, the 5-year relative survival rate under SEER 2016–2022 is 98.2%. Both figures are nationwide statistics, not results from any single hospital.
• Prostate cancer often progresses slowly, so active surveillance—monitoring at set intervals without immediate treatment—is a standard option for low-risk cases.
• Treatment and prognosis are determined not by stage alone but by a combination of PSA level, Gleason score (grade group), the risk group derived from staging, age, and coexisting conditions.
• Even at the metastatic stage, long-term disease control centered on hormone therapy is possible, though this stage is not treated with curative intent.

What does a 96.9% survival rate actually mean?

• This figure is not a prediction for any individual outcome—it is an average for the entire group of patients diagnosed during the same period.
• According to National Cancer Registry Statistics 2019–2023, Korean prostate cancer patients are, on average, alive at the 5-year mark at a rate of 96.9% relative to the general population of the same age and sex. The rise in survival is explained largely by the widespread use of PSA blood tests, which has increased the proportion of cases diagnosed early, while the cancer is still confined locally.
• An individual's actual course can vary enormously—from low-risk disease to metastatic stage—depending on PSA level, Gleason grade group, whether the cancer remains confined within the prostate, and whether it has spread to lymph nodes or bone. This single average figure cannot be used to judge any one person's outlook.

How do treatment and prognosis differ by risk group?

• Low-risk disease—characterized by low PSA, the lowest grade group, and a small tumor confined within the prostate—is typically managed with active surveillance, checking PSA and MRI at set intervals rather than treating immediately.
• For intermediate-risk disease, both radical prostatectomy and radiation therapy are standard options; the choice is often made based on differences in the type of side effects rather than differences in outcome.
• High-risk and locally advanced disease usually involves removing the pelvic lymph nodes during surgery along with additional radiation therapy; if radiation therapy is chosen, several years of hormone therapy is included as standard.
• At the metastatic stage, hormone therapy that blocks male hormones forms the backbone of treatment, and it has become standard to combine this from the start with anti-androgen agents or chemotherapy. If hormone therapy stops working, other drug classes, chemotherapy, or PSMA-targeted radioligand therapy are considered.

What is the typical sequence from diagnosis to treatment?

• Step 1: If PSA blood test levels are elevated or a digital rectal exam finds an abnormality, prostate MRI is performed first.
• Step 2: If MRI reveals a suspicious area, an MRI-fusion biopsy targets that spot to obtain the Gleason score and grade group (levels 1 through 5).
• Step 3: MRI is used to check for invasion beyond the prostate capsule; for higher-risk cases, a bone scan or PSMA PET is added to check for metastasis.
• Step 4: PSA, grade group, and stage are combined to determine the risk group, and the appropriate approach—surgery, radiation therapy, hormone therapy, or active surveillance—is selected.
• Step 5: After treatment, PSA is measured at set intervals to monitor for recurrence.

FAQ — Can someone live a long time even after bone metastasis?

Metastatic prostate cancer can be managed for a long period with hormone therapy as the backbone of treatment. Combining drugs from the outset has become the standard approach, often paired with bone-protective medication and radiation therapy to relieve pain. That said, this stage is not treated with curative intent, and the length of disease control varies from person to person.

FAQ — Whose survival results are these—a specific hospital's?

These are not results from any specific hospital but nationwide statistics for all of Korea (National Cancer Registry Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry). Under Korean medical law, individual hospitals' outcome data cannot be used in advertising, and actual results vary substantially depending on risk group and stage.

Sources and disclaimer

• This article was written based on National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea Central Cancer Registry), U.S. SEER 2016–2022 data, the National Cancer Information Center of the National Cancer Center Korea, and NCCN patient guidelines.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with a physician.